SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 9, 2018--
Veracyte,
Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson,
chairman and chief executive officer, will present at the Canaccord
Genuity Medical Technologies & Diagnostics Forum on Thursday, November
15, 2018, at 9:00 a.m. Eastern Time (ET).
A live audio webcast of the company’s presentation will be available by
visiting Veracyte’s website at http://investor.veracyte.com/events-presentations.
A replay of the webcast will be available for 90 days following the
conclusion of the live presentation broadcast.
About Veracyte
Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that
improves patient care by providing trustworthy and actionable answers to
challenging clinical questions. The company's products uniquely combine
advanced genomic technology, clinical science and machine learning to
provide answers that give physicians and patients a clear path forward,
informing both diagnosis and treatment decisions without the need for
costly, risky surgeries that are often unnecessary. Since its founding
in 2008, Veracyte has commercialized three genomic tests, which are
transforming the diagnosis of thyroid cancer, lung cancer and idiopathic
pulmonary fibrosis and collectively target a $2 billion market
opportunity. Veracyte is based in South San Francisco, California. For
more information, please visit www.veracyte.com
and follow the company on Twitter (@veracyte).
View source version on businesswire.com: https://www.businesswire.com/news/home/20181109005135/en/
Source: Veracyte, Inc.
Veracyte Media & Investor Contact:
Angie McCabe,
650-243-6371
Vice President, Investor Relations & Corporate
Communications
angie@veracyte.com